Abstract 96P
Background
Flot (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is the standard regimen for perioperative chemotherapy in locally advanced gastric cancer. Preoperative chemotherapy downstages the tumor, increases pathological response. Patients receiving flot are hospitalised for more than a day. This study compares it with dox (docetaxel, oxaliplatin and capecitabine) - a daycare regimen, as capecitabine has already been proven non-inferior to 5-fluorouracil in advanced gastric cancer.
Methods
62 patients were enrolled in this prospective observational study. 31 patients received 4 doses of 2 weekly infusions of 5-fluorouracil- 2600 mg/m2, leucovorin - 200 mg/m2, oxaliplatin - 85 mg/m2, docetaxel- 50 mg/m2 on day 1. Rest 31 received 3 doses of 3 weekly infusions of docetaxel- 60 mg/m2, oxaliplatin - 130 mg/m2 on day 1 and tablet capecitabine -1000 mg/m2 bid for 14 days. Radiological response to chemotherapy were analysed 2 weeks after chemotherapy completion and categorised into stable disease, partial response, progressive disease and complete response according to recist criteria version 1.1. Chi-square test was applied for analysis.
Results
In flot arm, 38.1 % (8) had partial response, 66.7 % (12) had progressive disease, 55 % (11) had stable disease radiologically. In dox arm, 61.9 %(13) had partial response, 33.3 % (6) had progressive disease, 45 % (9) had stable disease radiologically . 3 patients in dox regimen did not have evaluation (1 lost to follow-up; 2 died during the course of treatment). P value obtained was 0.197. The radiological response to chemotherapy was not statistically significant between two groups.
Conclusions
The radiological response to chemotherapy post flot or dox regimen is not statistically different. Dox maybe considered as an alternative regimen to flot in neoadjuvant chemotherapy in locally advanced gastric cancer patients with the advantage being a daycare procedure, requiring less resources and manpower.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Presenter: Kazuaki Harada
Session: Poster viewing 02
100P - A prospective single arm study evaluating the outcome of neoadjuvant chemotherapy in locally advanced/border line resectable gall bladder cancer
Presenter: Pulkit Nag
Session: Poster viewing 02
101P - Cachexia index and sarcopenia in patients with advanced gastrointestinal cancer treated with chemotherapy during exercise intervention
Presenter: Song Ee Park
Session: Poster viewing 02
102P - A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Presenter: Caiyun Nie
Session: Poster viewing 02
103P - Concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 02
104P - A multi-institutional epidemiological and oncological profile of gastrointestinal stromal tumors in the Lebanese population
Presenter: Mohamad Hadi El Charif
Session: Poster viewing 02
105P - The efficacy of nivolumab monotherapy for advanced gastric cancer depends on the HER2 status
Presenter: Yuichiro Nishibori
Session: Poster viewing 02
106P - Clinicopathologic and prognostic significance of FBXL5 expression in hepatocellular carcinoma
Presenter: Yoon Ah Cho
Session: Poster viewing 02
107P - Preliminary result of anatomical hepatectomy on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma
Presenter: Xiaozhun Huang
Session: Poster viewing 02
108P - A meta-analysis of PD-1 inhibitors for the treatment of advanced esophageal squamous cell carcinoma in second-line setting
Presenter: Barinder Singh
Session: Poster viewing 02